-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MannKind (NASDAQ:MNKD) Stock Passes Above 200 Day Moving Average of $3.72
MannKind (NASDAQ:MNKD) Stock Passes Above 200 Day Moving Average of $3.72
MannKind Co. (NASDAQ:MNKD – Get Rating)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.72 and traded as high as $3.72. MannKind shares last traded at $3.57, with a volume of 19,594,710 shares traded.
MannKind Stock Performance
The company's fifty day moving average is $3.85 and its two-hundred day moving average is $3.72. The company has a market cap of $901.66 million, a price-to-earnings ratio of -10.50 and a beta of 1.74.
Get MannKind alerts:MannKind (NASDAQ:MNKD – Get Rating) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $18.90 million during the quarter, compared to analyst estimates of $15.62 million. During the same quarter in the previous year, the company posted ($0.05) EPS. The company's quarterly revenue was down 18.9% on a year-over-year basis. On average, sell-side analysts anticipate that MannKind Co. will post -0.38 EPS for the current fiscal year.
Insiders Place Their Bets
In other MannKind news, EVP David Thomson sold 7,000 shares of the company's stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $3.67, for a total value of $25,690.00. Following the sale, the executive vice president now owns 726,035 shares in the company, valued at approximately $2,664,548.45. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have purchased 18,100 shares of company stock worth $53,033. Corporate insiders own 2.30% of the company's stock.Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in MNKD. Oakworth Capital Inc. purchased a new position in MannKind in the 1st quarter valued at $25,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of MannKind by 277.9% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 7,056 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 5,189 shares during the last quarter. Nisa Investment Advisors LLC acquired a new stake in shares of MannKind in the 2nd quarter worth $30,000. International Assets Investment Management LLC acquired a new stake in shares of MannKind in the 1st quarter worth $39,000. Finally, Cetera Advisors LLC acquired a new stake in shares of MannKind in the 2nd quarter worth $51,000. Hedge funds and other institutional investors own 46.83% of the company's stock.
About MannKind
(Get Rating)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.
Featured Stories
- Get a free copy of the StockNews.com research report on MannKind (MNKD)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.
MannKind Co. (NASDAQ:MNKD – Get Rating)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.72 and traded as high as $3.72. MannKind shares last traded at $3.57, with a volume of 19,594,710 shares traded.
在週五的交易中，納斯達克的股價突破了200日移動均線，200日移動均線切入位為3.72美元，最高交易價格為3.72美元。該公司股票最新報3.57美元，總成交量為19,594,710股。
MannKind Stock Performance
MannKind股票表現
The company's fifty day moving average is $3.85 and its two-hundred day moving average is $3.72. The company has a market cap of $901.66 million, a price-to-earnings ratio of -10.50 and a beta of 1.74.
該公司的50日移動均線切入位在3.85美元，200日移動均線切入位在3.72美元。該公司市值為9.0166億美元，市盈率為-10.50倍，貝塔係數為1.74。
MannKind (NASDAQ:MNKD – Get Rating) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $18.90 million during the quarter, compared to analyst estimates of $15.62 million. During the same quarter in the previous year, the company posted ($0.05) EPS. The company's quarterly revenue was down 18.9% on a year-over-year basis. On average, sell-side analysts anticipate that MannKind Co. will post -0.38 EPS for the current fiscal year.
曼肯德(納斯達克代碼：MNKD-GET Rating)最近一次發佈季度收益數據是在8月9日(星期二)。這家生物製藥公司公佈了該季度每股收益(0.11美元)，低於普遍預期的(0.09美元)和(0.02美元)。該業務本季度營收為1890萬美元，而分析師預期為1562萬美元。在去年同期，該公司公佈了每股收益(0.05美元)。該公司季度營收同比下降18.9%。賣方分析師平均預計，曼肯德公司本財年每股收益將為0.38歐元。
Insiders Place Their Bets
內部人士下注
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds and other institutional investors have recently made changes to their positions in MNKD. Oakworth Capital Inc. purchased a new position in MannKind in the 1st quarter valued at $25,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of MannKind by 277.9% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 7,056 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 5,189 shares during the last quarter. Nisa Investment Advisors LLC acquired a new stake in shares of MannKind in the 2nd quarter worth $30,000. International Assets Investment Management LLC acquired a new stake in shares of MannKind in the 1st quarter worth $39,000. Finally, Cetera Advisors LLC acquired a new stake in shares of MannKind in the 2nd quarter worth $51,000. Hedge funds and other institutional investors own 46.83% of the company's stock.
一些對衝基金和其他機構投資者最近改變了他們在MNKD的頭寸。Oakworth Capital Inc.在第一季度購買了MannKind的新頭寸，價值2.5萬美元。西北互惠財富管理公司在第二季度增持了277.9%的曼肯德股票。西北互惠財富管理公司在上個季度增持了5,189股後，現在持有7,056股這家生物製藥公司的股票，價值27,000美元。NISA Investment Advisors LLC在第二季度收購了價值3萬美元的MannKind新股。國際資產投資管理公司在第一季度收購了價值3.9萬美元的MannKind新股。最後，Cetera Advisors LLC在第二季度收購了價值51,000美元的MannKind新股。對衝基金和其他機構投資者持有該公司46.83%的股份。
About MannKind
關於曼肯德
(Get Rating)
(獲取評級)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.
MannKind公司是一家生物製藥公司，在美國專注於內分泌和孤兒肺部疾病吸入性治療產品的開發和商業化。它提供Afrezza，一種吸入型胰島素，用於改善成人糖尿病患者的血糖控制。它還向成人和兒童內分泌學家以及其他治療甲狀腺功能減退症的醫療保健提供者推廣胸腺功能。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on MannKind (MNKD)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- 免費獲取StockNews.com關於MannKind的研究報告(MNKD)
- 股市：紅海中的三座強國
- 第四季度值得考慮的3家銀行
- 有什麼辦法可以治癒Teladoc股票的問題嗎？
- MarketBeat：回顧一週9/12-9/16
- 沒有人告訴這三隻股票這是下跌的一週
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.
接受《MannKind Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對MannKind和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧